Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Retained Earnings
Editas Medicine Inc
Retained Earnings Peer Comparison
Competitive Retained Earnings Analysis
Latest Figures & CAGR of Competitors
Company | Retained Earnings | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Retained Earnings
-$1.3B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Retained Earnings
-$1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Retained Earnings
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Retained Earnings
-$27.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-15%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Retained Earnings
$10.1B
|
CAGR 3-Years
128%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Retained Earnings
$28B
|
CAGR 3-Years
33%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
See Also
What is Editas Medicine Inc's Retained Earnings?
Retained Earnings
-1.3B
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Retained Earnings amounts to -1.3B USD.
What is Editas Medicine Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-24%
Over the last year, the Retained Earnings growth was -15%. The average annual Retained Earnings growth rates for Editas Medicine Inc have been -21% over the past three years , -24% over the past five years .